Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese

BMC Cancer

Table 2 Incidence of non-melanoma skin cancer by rosiglitazone exposure at entry

Rosiglitazone use	Case number	Incident skin cancer	%	Person-years	Incidence rate (per 100,000 person-years)
Never users	783321	2084	0.27	2714745.08	76.77
Ever users	103097	250	0.24	362846.42	68.90
P value			0.1653
Duration of therapy (months)
Never users	783321	2084	0.27	2714745.08	76.77
<3.73	33039	93	0.28	112752.67	82.48
3.73-13.77	35108	88	0.25	123278.50	71.38
>13.77	34950	69	0.20	126815.25	54.41
P value			0.0847
Cumulative dose (mg)
Never users	783321	2084	0.27	2714745.08	76.77
<448	32942	90	0.27	112711.50	79.85
448-1752	35078	86	0.25	123002.83	69.92
>1752	35077	74	0.21	127132.08	58.21
P value			0.2172

ISSN: 1471-2407